Nearly $1 Billion: Another ADC Out‑Licensing Deal from China

On the evening of October 9, Micurx (688373.SH) announced that it plans to sign two agreements with Switzerland-based ClearideBio Therapeutics AG: one is a global exclusive license agreement for the MRX-23 project, and the other is a multi-project option collaboration agreement based on the company's independently developed "STOPIN" antibody-drug conjugate (ADC) platform.

The former involves an upfront payment of $1 million, with a nominal cap of $223 million in total for R&D, regulatory, and commercial milestones; the latter stipulates that ClearideBio may exercise options for up to six targets or target combination projects, with a cumulative payment cap of $750 million if all options are exercised and all milestones are fully achieved.

MRX-23, one of the assets in question, is an HER2-targeting ADC candidate drug independently developed by MICURX and is currently in the preclinical stage. According to disclosures made by the company on its investor relations platform, this project incorporates MICURX's self-developed next-generation camptothecin toxin and an optimized linker, with the design objective of enhancing efficacy and safety.

Antibody-drug conjugates (ADCs) consist of three components: an antibody, a linker, and a cytotoxic payload, which can be likened to equipping chemotherapeutic toxins with an antibody-guided targeting system. Camptothecin-based payloads have already seen relatively mature application in the ADC field.

Over the past decade, topoisomerase I (TOP1) inhibitor payloads, represented by DXd, have gradually become a key technological approach in the commercialization of antibody-drug conjugates (ADCs). According to data from Global Market Insights, in 2025, TOP1 inhibitor payloads accounted for approximately 30.3% of the ADC market, with a compound annual growth rate (CAGR) of about 11.5%, second only to tubulin inhibitor payloads.

Nevertheless, this approach still faces challenges: the payload exhibits significant cytotoxicity. Premature drug release or non-specific distribution may increase exposure to normal tissues and associated toxicity, thereby limiting the therapeutic window.

MICURX's STOPIN platform is centered on the optimization of camptothecin-based payloads. Its design strategy involves modulating the pharmacokinetic properties of the payload to minimize unnecessary systemic exposure while preserving antitumor activity as much as possible. However, whether this design objective can translate into tangible advantages in efficacy and safety remains to be validated through further preclinical data and clinical studies.

Therefore, the scope of this collaboration is no longer limited to the candidate drug MRX-23, but also extends to multiple future projects potentially developed on the STOPIN platform.

For platform technologies, the true value lies not only in the ability to design a candidate molecule, but more importantly, in the capacity to consistently translate technological advantages into verifiable efficacy and safety profiles across diverse projects, ultimately driving products into clinical development.

MICURX, founded in 2007, has long focused on the research and development of anti-infective drugs. Its core product, contezolid (MRX-I), has been approved for marketing in China, and the company has also laid out other R&D projects in both anti-infective and non-anti-infective areas. MRX-23 represents the extension of its R&D pipeline into the field of oncology treatment.

From this transaction, it is evident that MICURX provides candidate drugs and technical expertise related to its ADC platform, while transferring the responsibilities for subsequent global development and commercialization to its partner through a licensing agreement. For a company primarily focused on anti-infective small molecules, the global clinical development and commercialization of ADCs represent a task requiring different resource allocations and capability structures.

The acquirer, ClearideBio, is an ADC R&D company founded in December 2025 and headquartered in Basel, Switzerland.

Although appearing as a "10-month-old rookie," the company's track record is far from thin. Its two co-founders previously served as core team members at multiple ADC companies, with product development and clinical translation experience spanning eight ADC technology platforms. The company has also secured investment support from investors including the corporate venture capital arm of Lotte Holdings.

ClearideBio's official website positions its R&D focus on next-generation antibody-drug conjugates (ADCs), emphasizing payload innovation, the balance between efficacy and tolerability, and data-driven R&D decision-making to mitigate development risks.

From this positioning, ClearideBio's business model does not appear to aim for end-to-end independent advancement of clinical development. It is more likely to operate as an "ADC asset assembler," rapidly building a licensable portfolio by in-licensing differentiated payload platforms and leveraging its own capabilities in antibody engineering and payload design.

Micurx also clarified in its announcement that ClearideBio will be responsible for the subsequent global development and commercialization of MRX-23 and the platform projects for which options have been exercised, while Micurx retains the core intellectual property rights of the platform technology and the contingent economic benefits stipulated in the agreement. In other words, Micurx provides the "payload vehicle," while ClearideBio contributes the "development capabilities and overseas channels."

However, it is also important to recognize that ClearideBio was established relatively recently and remains in its early stages of development. The team's prior experience cannot be directly equated with the company's own financial strength, organizational capabilities, and actual project execution performance.

The complementarity of this transaction is clear, while its subsequent execution capability remains to be validated by project progress.

MICURX's deal with ClearideBio comes precisely at the inflection point where the logic for Chinese-made ADCs going global is shifting.

In the past, multinational pharmaceutical companies acquiring Chinese ADCs were buying "certainty"—Phase II data, validated targets, and predictable regulatory pathways. Buyers paid a premium for certainty, while sellers traded clinical progress for cash.

However, as TOP1 inhibitor payloads have been successfully validated across multiple commercialized products, engineering differences in payloads, linkers, and conjugation methods are replacing the target itself as the primary battleground for ADC competition.

According to Global Market Insights, the market share of TOP1 inhibitor payloads in the ADC market reached 30.3% in 2025, second only to tubulin inhibitors. As the mainstream payload pathways are validated, the next source of premium is no longer "which path to take," but "who can broaden this path."

This has directly altered the underlying structure of transactions. While early-stage asset licensing continues, headline deals increasingly embed platform options—buyers are no longer paying solely for a single molecule in hand, but also for the potential to "generate multiple additional molecules using the same engineering logic." The valuation anchor is shifting from "discounted cash flow based on known data" to "option pricing based on latent capabilities."

This shift also imposes higher demands on both buyers and sellers. Buyers must possess the ability to independently evaluate early-stage technologies, while sellers need to demonstrate that their platform is not a one-off stroke of luck, but rather a reproducible engineering capability.

The realization of option value ultimately hinges on clinical evidence—high-value milestones do not prove technological maturity, nor can transaction amounts substitute for data.

The platform's long-term moat lies not in the platform itself, but in its repeatedly validated molecular design capabilities, consistent development quality, and the transferability of its advantages across different targets and indications.

In the field of ADCs, where technological iteration far outpaces clinical validation, the true determinant of this deal's quality is whether the STOPIN platform can generate human data under ClearideBio's stewardship.

Only those designs that pass clinical validation earlier will hold truly valuable options.